IsomAb Ltd, a UK-based biotechnology company, announced on March 18, 2026, the appointment of Dr. Philip Brainin as CEO and Board member.12
Dr. Brainin, a physician-scientist with expertise in clinical cardiology, venture investing, and cardiovascular medicine, will lead ISM-001 into clinical development for chronic stable angina (CSA), affecting 9 million US patients.1
ISM-001 is an isoform-specific antibody targeting VEGF-A165b to restore blood flow in ischemic disease, supported by strong preclinical data.1
Dr. Anker Lundemose appointed Chair of the Board, replacing Paul Edwards; company preparing for Series A fundraise.1
IsomAb, founded in 2022 as a University of Nottingham spin-out, focuses on isoform-specific antibodies for ischemic conditions.1
Sources:
1. https://www.prnewswire.com/news-releases/isomab-appoints-dr-philip-brainin-as-chief-executive-officer-302716474.html